Search Results - "S, Peters"

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy by Remon, J., Soria, J.-C., Peters, S.

Get full text

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Haanen, J.B.A.G., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J., Jordan, K.

Get full text

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Postmus, P.E., Kerr, K.M., Oudkerk, M., Senan, S., Waller, D.A., Vansteenkiste, J., Escriu, C., Peters, S.

Get full text

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A.R., Wick, W., Kostine, M., Peters, S., Jordan, K., Larkin, J.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing immunotherapy-related toxicity.•The guideline covers assessment, diagnosis and…”
Get full text

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Planchard, D, Popat, S, Kerr, K, Novello, S, Smit, E F, Faivre-Finn, C, Mok, T S, Reck, M, Van Schil, P E, Hellmann, M D, Peters, S

Get full text

Increased striatal activity in adolescence benefits learning by Peters, S., Crone, E. A.

“…Adolescence is associated with enhanced striatal activity in response to rewards. This has been linked to increased risk-taking behavior and negative health…”
Get full text

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic by Chan, T.A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S.A., Stenzinger, A., Peters, S.

“…Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or…”
Get full text

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Novello, S, Barlesi, F, Califano, R, Cufer, T, Ekman, S, Levra, M Giaj, Kerr, K, Popat, S, Reck, M, Senan, S, Simo, G V, Vansteenkiste, J, Peters, S

Get full text

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Reck, M, Popat, S, Reinmuth, N, De Ruysscher, D, Kerr, K M, Peters, S

Get full text

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Peters, S, Adjei, A A, Gridelli, C, Reck, M, Kerr, K, Felip, E

Get full text

Creation of forest edges has a global impact on forest vertebrates by Pfeifer, M., Lefebvre, V., Peres, C. A., Banks-Leite, C., Wearn, O. R., Marsh, C. J., Butchart, S. H. M., Arroyo-Rodríguez, V., Barlow, J., Cerezo, A., Cisneros, L., D’Cruze, N., Faria, D., Hadley, A., Harris, S. M., Klingbeil, B. T., Kormann, U., Lens, L., Medina-Rangel, G. F., Morante-Filho, J. C., Olivier, P., Peters, S. L., Pidgeon, A., Ribeiro, D. B., Scherber, C., Schneider-Maunoury, L., Struebig, M., Urbina-Cardona, N., Watling, J. I., Willig, M. R., Wood, E. M., Ewers, R. M.

“…Forest edges influence more than half of the world’s forests and contribute to worldwide declines in biodiversity and ecosystem functions. However, predicting…”
Get full text

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy by Haanen, J., Ernstoff, M.S., Wang, Y., Menzies, A.M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J.A., Obeid, M.

“…Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high…”
Get full text

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Früh, M, De Ruysscher, D, Popat, S, Crinò, L, Peters, S, Felip, E

Get full text

Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C., Peters, S.

Get full text

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study by Gadgeel, S., Peters, S., Mok, T., Shaw, A.T., Kim, D.W., Ou, S.I., Pérol, M., Wrona, A., Novello, S., Rosell, R., Zeaiter, A., Liu, T., Nüesch, E., Balas, B., Camidge, D.R.

“…The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met…”
Get full text

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Vansteenkiste, J, De Ruysscher, D, Eberhardt, W E E, Lim, E, Senan, S, Felip, E, Peters, S

Get full text

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective by Jones, HM, Chen, Y, Gibson, C, Heimbach, T, Parrott, N, Peters, SA, Snoeys, J, Upreti, VV, Zheng, M, Hall, SD

“…The application of physiologically based pharmacokinetic (PBPK) modeling has developed rapidly within the pharmaceutical industry and is becoming an integral…”
Get full text

Optimizing panel-based tumor mutational burden (TMB) measurement by Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., Swanton, C., Schirmacher, P., Stenzinger, A.

“…Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as…”
Get full text

Current status of immune checkpoint inhibition in early-stage NSCLC by Vansteenkiste, J., Wauters, E., Reymen, B., Ackermann, C.J., Peters, S., De Ruysscher, D.

“…Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies…”
Get full text

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 by Spigel, D.R., Vicente, D., Ciuleanu, T.E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., Reck, M.

“…Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously…”
Get full text